Back to Main

Faculty Detail    
Name MARK N PRICHARD
 
Campus Address CHB 128 Zip 0011
Phone 205-934-1990
E-mail mprichar@uab.edu
Other websites http://www.uab.edu/medicine/peds/macsynergy
     


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Pediatrics   Ped - Infectious Disease Professor
Secondary  Cell, Developmntl, & Integrative Biology  Cell, Developmntl, & Integrative Biology Professor
Secondary  Microbiology  Microbiology Associate Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor

Biographical Sketch 
Dr. Prichard received his Ph.D. from the University of Michigan in the Department of Microbiology and Immunology. He did his postdoctoral training in the laboratory of Dr. Ed Mocarski at Stanford University. He then spent several years in the biotech industry and was involved in the development of Flumist while employed at MedImmune Vaccines Inc. He is a Professor of Pediatrics at the University of Alabama at Birmingham where he is also the Director of the Diagnostic Virology Laboratory. He is an Editor of the journal, Antiviral Research, and is coauthor of more than 80 publications, book chapters and review articles, as well as the MacSynergy II analytical software. Current research interests include the discovery of antiviral drugs for DNA viruses and defining their activity at the molecular level.

Society Memberships
Organization Name Position Held Org Link
American Society for Microbiology     
American Society for Virology     
Antiviral Congress  Scientific Committee  http://www.antivirals.elsevier.com/index.html 
Antiviral Research  Editor  http://www.journals.elsevier.com/antiviral-research/ 
International Society for Antiviral Research  Board Member, Program Chair  http://www.isar-icar.com/ 

Research/Clinical Interest
Title
Antiviral drugs and their mechanism of action
Description
Studies in the lab focus on the discovery of new antiviral drugs for herpesviruses, orthopoxviruses, and papovaviruses. This work has identified a number of novel targets for antiviral therapy and help to characterize unrecognized aspects of viral replication.

Selected Publications 
Publication PUBMEDID
Prichard MN*, Kern ER, Hartline CB, Lanier ER, Quenelle DC. CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections. Antimicrob Agents Chemother. 2011;55(10):4728-34  3186990 
James SH, Hartline CB, Harden EA, Driebe EM, Schupp JM, Engelthaler DM, Keim PS, Bowlin TL, Kern ER, and Prichard MN*. Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antimicrob Agents Chemother. 2011;55(10):4682-91  3186952 
Prichard MN*, Sztul E, Daily SL, Perry AL, Frederick SL, Gill RB, Hartline CB, Streblow DN, Varnum SM, Smith RD, Kern ER. Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J Virol. 2008;82(10):5054-67  2346732 
Stern-Ginossar, N., Elefant,N., Zimmermann, A., Wolf, D.G., Saleh, N., Biton, M., Horwitz, E., Prokocimer, Z., Prichard, M.N., Hahn, G., Goldman-Wohl, D., Greenfield, C., Yagel, S., Hengel, H., Altuvia, Y., Margalit, H., Mandelboim, O. 2007. Host immune system gene targeting by a viral miRNA. Science. 317: 376-381.  17641203 
Prichard, M.N.*, Keith, K.A., Johnson M.P., Harden, E.A., McBrayer, A., Luo, M., Qiu, S., Chattopadhyay, D., Fan, X., Torrence, P.F., and Kern, E.R. 2007. Selective phosphorylation of antiviral drugs by the vaccinia virus thymidine kinase. Antimicrob. Agents Chemother. 51:1795–1803.  17325220 
Prichard, M.N.*, Britt, W.J., Daily, S.L., Hartline, C.A., and Kern E.R. 2005. Human cytomegalovirus UL97 kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J. Virol. 79(24):15494-15502.:1.   16306620  
Williams-Aziz, S.L., Hartline, C.B., Harden, E.A., Daily, S.M, Prichard, M.N., Kushner, N.L., Beadle, J.R., Wan, W.B., Hostetler, K.Y., and Kern, E.R. 2005. Comparative activity of ether lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents Chemother. 49:3724-3733.  16127046 
Kreissel, J.D., Spruance, S.L., Prichard, M.N., Parker, J.N. and Kern, E.R. 2005. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J. Infect. Dis. 192(1):156-161.  15942905  
Wolf, D.G., Courcelle, C.T., Prichard, M.N., and E.S.Mocarski. 2001. Distinct and separate roles of herpesvirus conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc. Natl. Acad. Sci. U.S.A. 98: 1895-1900.   11172047  
Prichard, M.N.*, N. Gao, S. Jairath, G. Mulamba, P. Krosky,D.M. Coen, B.O. Parker, and G.S. Pari. 1999. A Recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol. 73:5663-5670.   10364316 
Prichard, M.N. and C. Shipman, Jr. 1990. (Review) A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-206.  2088205 
Prichard, M.N.*, Lawlor, H.A., Duke, G.W., Dixon, M.L., Wang, Z., Mo, C., Bidanset, D., Kemble, G.W., and Kern, E.R. 2005. Human cytomegalovirus uracil DNA glycosylase associates with ppUL44 and accelerates the accumulation of genomic DNA. Virol. J. 2:55.  16022730 

Keywords
antiviral, vaccine, protein kinase, virology